Genmab — December 2023
-
Biotekstjerneskud holder tæt om aftaler med Novo Nordisk og Genmab
Hemabs hovedaktiv er baseret på teknologi fra Genmab samt et produkt opdaget hos Novo Nordisk, og licenserne for begge er ikke gratis, lyder det fra Hemab.
(medwatch.dk)
-
AbbVie's Humira, J&J's Darzalex top ICER's annual price-hike list. https://www.fiercepharma.com/pharma/abbvies-humira-takes-back-its-top-spot-icers-annual-list-unsupported-price-hikes
-
Tidlige effektdata for teclistamab mod RRMM i real-world setting er lovende https://haematologisktidsskrift.dk/sygdomme/myeloma/1283-tidlige-effektdata-for-teclistamab-mod-rrmm-i-real-world-setting-er-lovende.html
-
Targeteret behandling af RRMM-patienter med t(11;14)-positiv sygdom rykker nærmere https://haematologisktidsskrift.dk/sygdomme/myeloma/1300-targeteret-behandling-af-rrmm-patienter-med-t-11-14-positiv-sygdom-rykker-naermere.html
-
Godmorgen

-
Hvorfor nu det fald?
-
Der var vel ikke noget dårligt ved ASH?
-
Kan det være denne Glofi præsentation? https://x.com/dochutchings/status/1734292449890296188?s=61&t=Ry4q9LC1jDgQzC__0QIEPg
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind